hERG Channels: From Antitargets to Novel Targets for Cancer Therapy

被引：36
作者：
Arcangeli, Annarosa [1 ]
Becchetti, Andrea [2 ]
机构：
[1] Univ Florence, Dept Expt & Clin Med, Viale GB Morgagni 50, I-50134 Florence, Italy
[2] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy
来源：
CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 01期
关键词：
TORSADE-DE-POINTES; DRUG DEVELOPMENT; ION CHANNELS; K+ CHANNELS;
D O I：
10.1158/1078-0432.CCR-16-2322
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K+ channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to fatal arrhythmias in humans. (C) 2016 AACR.
引用
收藏
页码：3 / 5
页数：3
相关论文
共 12 条
  • [1] Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy
    Arcangeli, A.
    Crociani, O.
    Lastraioli, E.
    Masi, A.
    Pillozzi, S.
    Becchetti, A.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2009, 16 (01) : 66 - 93
  • [2] Novel perspectives in cancer therapy: Targeting ion channels
    Arcangeli, Annarosa
    Becchetti, Andrea
    [J]. DRUG RESISTANCE UPDATES, 2015, 21-22 : 11 - 19
  • [3] New Pyrimido-Indole Compound CD-160130 Preferentially Inhibits the KV11.1B Isoform and Produces Antileukemic Effects without Cardiotoxicity
    Gasparoli, Luca
    D'Amico, Massimo
    Masselli, Marika
    Pillozzi, Serena
    Caves, Rachel
    Khuwaileh, Rawan
    Tiedke, Wolfgang
    Mugridge, Kenneth
    Pratesi, Alessandro
    Mitcheson, John S.
    Basso, Giuseppe
    Becchetti, Andrea
    Arcangeli, Annarosa
    [J]. MOLECULAR PHARMACOLOGY, 2015, 87 (02) : 183 - 196
  • [4] Novel roles for hERG K+ channels in cell proliferation and apoptosis
    Jehle, J.
    Schweizer, P. A.
    Katus, H. A.
    Thomas, D.
    [J]. CELL DEATH & DISEASE, 2011, 2 : e193 - e193
  • [5] MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes
    Kramer, James
    Obejero-Paz, Carlos A.
    Myatt, Glenn
    Kuryshev, Yuri A.
    Bruening-Wright, Andrew
    Verducci, Joseph S.
    Brown, Arthur M.
    [J]. SCIENTIFIC REPORTS, 2013, 3
  • [6] Mitcheson J, 2015, RSC DRUG DISCOV, V39, P258
  • [7] Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels
    Pillozzi, S.
    Masselli, M.
    Gasparoli, L.
    D'Amico, M.
    Polletta, L.
    Veltroni, M.
    Favre, C.
    Basso, G.
    Becchetti, A.
    Arcangeli, A.
    [J]. BLOOD CANCER JOURNAL, 2016, 6 : e423 - e423
  • [8] Administration of Non-Torsadogenic human Ether-a-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG-Expressing Glioblastoma Patients
    Pointer, Kelli B.
    Clark, Paul A.
    Eliceiri, Kevin W.
    Salamat, M. Shahriar
    Robertson, Gail A.
    Kuo, John S.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (01) : 73 - 80
  • [9] The hERG K+ channel:: target and antitarget strategies in drug development
    Raschi, Emanuel
    Vasina, Valentina
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    [J]. PHARMACOLOGICAL RESEARCH, 2008, 57 (03) : 181 - 195
  • [10] Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
    Redfern, WS
    Carlsson, L
    Davis, AS
    Lynch, WG
    MacKenzie, I
    Palethorpe, S
    Siegl, PKS
    Strang, I
    Sullivan, AT
    Wallis, R
    Camm, AJ
    Hammond, TG
    [J]. CARDIOVASCULAR RESEARCH, 2003, 58 (01) : 32 - 45
12